Tylenol Label Warning Complaint Ruling Preempts OTC Monograph Federal Preemption Question

Preemption not discussed in ruling dismissing plaintiff experts’ testimony other than to note court previously rejected Kenvue’s motion to dismiss based on a preemption argument.

• Source: Shutterstock

A question about whether federal preemption precludes challenges to the safety and labeling of drugs available under a Food and Drug Administration OTC monograph won’t be answered in litigation alleging acetaminophen labeling fails to warn about potential risks.

More from Regulation

More from Policy & Regulation

People On The Move: Appointments At Pharma Deutschland, MHRA, Futura

 
• By 

A round-up of the latest industry moves in Europe: Pharma Deutschland elects board of new Brussels operation; MHRA's new CEO gets to work; Futura names non-executive director.

Marketplace Results After FDA OTC Monograph Overhaul Rely On OMUFA Reauthorization

 

“If this doesn’t get reauthorized, look at the number of the ingredients out there, the number of products, what would happen all those products out there for the consumer, on that shelf, in the drugstore or someplace?” says Rep. Bob Latta during House hearing.

Democrats Torch Trump’s HHS Layoffs During House Hearing On OMUFA Reauthorization

 

Energy and Commerce Health Subcommittee Democrats focus on criticizing HHS Secretary Kennedy’s RIF announcement, including 3,500 FDA jobs among cuts across HHS agencies. “If we reauthorize it, will it continue?” Texas representative Lizzie Fletcher asks of OMUFA.